Biology subjects

Tassoni-Tsuchida, E.

Publications and source records attributed to Tassoni-Tsuchida, E..

2 recordsLinked to original sources

bioRxiv2026

Nup42 safeguards heat-induced mRNAs from nuclear condensation tosupport chaperone synthesis

Cells exposed to acute stress selectively express stress-adaptive genes while repressing growth-related genes. Upon heat shock, most pre-existing mRNAs localize to translationally repressed biomolecular condensates. How heat-induced mRNAs evade condensation and remain translationally competent remains unclear. Here, we show that ribosomal protein-coding transcripts preferentially accumulate in condensates during heat shock, whereas heat-induced chaperone mRNAs are selectively excluded and preferentially translated. Using a whole-genome CRISPRi screening platform, Fractionation of Reporter-Seq (FRep-Seq), we identify the nucleoporin Nup42 as the strongest suppressor of heat-induced mRNA condensation. Loss of Nup42 triggers temperature- and transcription-dependent nuclear condensation of chaperone mRNAs, which are exported but remain translationally incompetent, leading to impaired chaperone production and thermosensitivity. Co-transcriptional mRNP packaging is a critical determinant of condensation in the absence of Nup42. Together, our findings reveal a nuclear, translation-independent layer of mRNP solubility control that enables heat shock gene expression.

molecular biology↗

bioRxiv2021

Small molecule v-ATPase inhibitor Etidronate lowers levels of ALS protein ataxin-2

Antisense oligonucleotide therapy targeting ATXN2--a gene in which mutations cause neurodegenerative diseases spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis--has entered clinical trials in humans. Additional methods to lower ataxin-2 levels would be beneficial not only in uncovering potentially cheaper or less invasive therapies, but also in gaining greater mechanistic insight into how ataxin-2 is normally regulated. We performed a genome-wide fluorescence activated cell sorting (FACS)-based CRISPR screen in human cells and identified multiple subunits of the lysosomal vacuolar ATPase (v-ATPase) as regulators of ataxin-2 levels. We demonstrate that Etidronate--a U.S. Food and Drug Administration (FDA)-approved drug that inhibits the v-ATPase--lowers ataxin-2 protein levels in mouse and human neurons. Moreover, oral administration of the drug to mice in their water supply and food is sufficient to lower ataxin-2 levels in the brain. Thus, we uncover Etidronate as a safe and inexpensive compound for lowering ataxin-2 levels and demonstrate the utility of FACS-based screens for identifying targets to modulate levels of human disease proteins.

neuroscience↗